Skip to main content
. 2020 Oct 12;180(12):1638–1646. doi: 10.1001/jamainternmed.2020.4748

Figure 4. Subgroup Analysis for All-Cause Mortality, Cardiac Mortality, and Noncardiac Mortality for Trials Using Drug-Eluting vs Bare-Metal Stents.

Figure 4.

ARTS indicates Arterial Revascularization Therapies Study; BEST, Randomized Comparison of Coronary Artery Bypass Surgery and Everolimus-Eluting Stent Implantation in the Treatment of Patients With Multivessel Coronary Artery Disease; CABG, coronary artery bypass grafting; ERACI II, Coronary Angioplasty With Stenting vs Coronary Bypass Surgery in Patients With Multiple-Vessel Disease; EXCEL, Evaluation of XIENCE vs Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization; FREEDOM, Future Revascularization Evaluation in Patients With Diabetes Mellitus: Optimal Management of Multivessel Disease; IRR, incidence rate ratio; MASS-II, Medicine, Angioplasty, or Surgery Study; NOBLE, Nordic–Baltic–British Left Main Revascularisation Study; PCI, percutaneous coronary intervention; PRECOMBAT, Premier of Randomized Comparison of Bypass Surgery vs Angioplasty Using Sirolimus-Eluting Stent in Patients With Left Main Coronary Artery Disease; SIMA, Stenting vs Internal Mammary Artery Grafting; SoS, Stent or Surgery; SYNTAX, Synergy Between PCI With Taxus and Cardiac Surgery; and VA CARDS, Veterans Affairs Coronary Artery Revascularization in Diabetes. Different size markers indicate 95% CIs.